1. Pink Sheet
  2. >>Geography
  3. >>Asia

Japan Faces GLP-1 Shortage As Off-Label Diet Use Surges

Grey Areas Between Regulations

 
• By Lisa Takagi

Despite repeated warnings by regulatory authorities and physicians’ associations, the demand for easy diet aids is impacting the supply of GLP-1 receptor antagonists in Japan.

The shortage suffers legal dilemma of off label use of drugs or use of unapproved drugs.
Japan GLP-1 shortages grow due to legal grey area of off-label use • Source: Shutterstock

Japan is facing a supply shortage of GLP-1 receptor antagonists for type 2 diabetes due to their off-label use as diet drugs, prompting the main manufacturers to restrict supplies and calls for their use only in officially approved indications.

Because of the high overall demand, both Novo Nordisk A/S and Eli Lilly and Company have had to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Asia

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

New Era Begins In Korea: Policy Predictions For Biopharma

 
• By Jung Won Shin

As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 
• By Eliza Slawther

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.